Nuclear receptor coactivators

Current Opinion in Cell Biology

Volumn 9, Issue 2, 1997, Pages 222-232

  Glass, Christopher K ^a   Rose, David W ^b   Rosenfeld, Michael G ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL NUCLEUS RECEPTOR; CELL RECEPTOR; LIGAND; RETINOIC ACID; STEROID; THYROID HORMONE;

MOLECULAR CLONING; PRIORITY JOURNAL; REVIEW; TRANSCRIPTION REGULATION;

EID: 0030937411     PISSN: 09550674     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0955-0674(97)80066-X     Document Type: Article

References (50)

1. Glass CK: Differential recognition of target genes by nuclear receptor monomers, dimers and heterodimers. Endocrine Rev 1994, 15:1503-1519.
2. Danielian PS, White R, Lees JA, Parker MG: Identification of a conserved region required for hormone-dependent transcriptional activation by steroid hormone receptors. EMBO J 1992, 11:1025-1033.
3. Barettino D, Vivanco Ruiz MM, Stunnenberg HG: Characterization of the ligand-dependent transactivation domain of thyroid hormone receptor. EMBO J 1994, 13:3039-3049.
4. Durand B, Saunders M, Gaudon C, Roy B, Losson R, Chambon P: Activation function 2 (AF-2) of retinoic acid receptor and 9-cis retinoic acid receptor: presence of a conserved autonomous constitutive activating domain and influence of the nature of the response element on AF-2 activity. EMBO J 1994, 13:5370-5382.
5. Tone Y, Collingwood TN, Adams M, Chatterjee VK: Functional analysis of a transactivation domain in the thyroid hormone beta receptor. J Biol Chem 1994, 269:31157-31161.
6. Bourguet W, Ruff M, Chambon P, Gronemeyer H, Moras D: Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-α. Nature 1995, 375:377-382. This paper provides the first crystal structure of a nuclear receptor ligand-binding domain. The overall structure has proven to be prototypic for the ligand-binding domains of other nuclear receptors. As the only available structure for an unliganded LBD, comparison with the structures of the liganded RAR and liganded TR LBDs suggests the nature of the conformational changes in receptor structure that are induced by the binding of ligand.
7. Renaud J-P, Rochel N, Ruff M, Vivat V, Chambon P, Gronemeyer H, Moras D: Crystal structure of the RAR-γ ligand-binding domain bound to all-trans retinoic acid. Nature 1995, 378:681-689. This paper describes the crystal structure of the liganded RAR LBD. The overall fold of the LBD is shown to be similar to that of the RXR LBD. The structure illustrates the relationship between all-trans retinoic acid and the ligand-binding pocket. The AF-2 region of the LBD, which is required for transcriptional activation, makes direct contact with the ligand, suggesting that it may play a structural role, in addition to a potential role in interacting with coactivator molecules. By comparing the liganded RAR structure with the unliganded RXR structure [6••], the authors suggest the nature of the conformational changes that might be induced in the LBD by retinoic acid.
8. Wagner RL, Apriletti JW, McGrath ME, West BL, Baxter JD, Fletterick RJ: A structural role for hormone in the thyroid hormone receptor. Nature 1995, 378:690-697. In this paper, the authors describe the structure of the liganded TR LBD. As in [7••], the overall fold of the LBD is shown to be similar to that of the RXR LBD, but is much more compact, suggesting a structural role of the ligand. As in the structure of the liganded RAR, the AF-2 region of the liganded TR is shown to be tightly packed against the ligand-binding domain and to contribute to the ligand-binding pocket.
9. Mangelsdorf DJ, Evans RM: The RXR heterodimers and orphan receptors. Cell 1995, 83:841-850.
10. Kliewer SA, Umesono K, Noonan DJ, Heyman RA, Evans RM: Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 1992, 358:771-774.
11. Kurokawa R, DiRenzo J, Boehm M, Sugarman J, Gloss B, Rosenfeld MG, Heyman RA, Glass CK: Regulation of retinoid signalling by receptor polarity and allosteric control of ligand binding. Nature 1994, 371:528-531.
12. Forman BM, Umesono K, Chen J, Evans RM: Unique response pathways are established by allosteric interactions among nuclear hormone receptors. Cell 1995, 81:541-550.
13. Chen J-Y, Clifford J, Zusi C, Starrett J, Tortolani D, Ostrowski J, Reczek PR, Chambon P, Gronemeyer H: Two distinct actions of retinoid-receptor ligands. Nature 1996, 382:819-822.
14. Meyer M, Gronemeyer H, Turcotte B, Bocquel M, Tasset D, Chambon P: Steroid hormone receptors compete for factors that mediate their enhancer function. Cell 1989, 57:433-442.
15. Halachmi S, Marden E, Martin G, MacKay H, Abbondanza C, Brown M: Estrogen receptor-associated proteins: possible mediators of hormone-induced transcription. Science 1994, 264:1455-1458.
16. Cavailles V, Dauvois S, Danielian PS, Parker MG: Interaction of proteins with transcriptionally active estrogen receptors. Proc Natl Acad Sci USA 1994, 91:10009-10013.
17. Hanstein B, Eckner R, DiRenzo J, Halachmi S, Liu H, Searcy B, Kurokawa R, Brown M: p300 is a component of an estrogen receptor coactivator complex. Proc Natl Acad Sci USA 1996, 93:11540-11545. In this paper, the authors demonstrate that p300 associates with the estrogen receptor in a ligand-dependent and AF-2-dependent manner. The association of p300 with the estrogen receptor is induced by estradiol, but not by an estrogen receptor antagonist. p300 is also shown to potentiate estrogen-dependent transcription, suggesting that it is a component of a nuclear receptor coactivator complex.
18. Kurokawa R, Söderström M, Hörlein A, Halachmi S, Brown M, Rosenfeld MG, Glass CK: Polarity-specific activities of retinoic acid receptors determined by a co-repressor. Nature 1995, 377:451-454.
19. Eggert M, Möws CC, Tripier D, Arnold R, Michel J, Nickel J, Schmidt S, Beato M, Renkawitz R: A fraction enriched in a novel glucocorticoid receptor-interacting protein stimulates receptor-dependent transcription in vitro. J Biol Chem 1995, 270:30755-30759.
20. Fondell JD, Ge H, Roeder RG: Ligand induction of a transcriptionally active thyroid hormone receptor coactivator complex. Proc Natl Acad Sci USA 1996, 93:8329-8333.
21. Lee JW, Ryan F, Swaffield JC, Johnston SA, Moore DD: Interaction of thyroid-hormone receptor with a conserved transcriptional mediator. Nature 1995, 374:91-94.
22. Swaffield J, Melcher K, Johnston S: A highly conserved ATPase protein as a mediator between acidic activation domains and the TATA-binding protein. Nature 1995, 374:88-91.
23. Rubin DM, Coux O, Wefes I, Hengartner C, Young RA, Goldberg AL, Finley D: Identification of the gal4 suppressor Sug1 as a subunit of the yeast 26S proteasome. Nature 1996, 379:655-657.
24. Le Douarin B, Zechel C, Garnier J-M, Lutz Y, Tora L, Pierrat B, Heery D, Gronemeyer H, Chambon P, Losson R: The N-terminal part of TIF1, a putative mediator of the ligand-dependent activation function (AF-2) of nuclear receptors, is fused to B-raf in the oncogenic protein T18. EMBO J 1995, 14:2020-2033.
25. Cavailles V, Dauvois S, L'Illorset F, Lopez G, Hoarc S, Kushner PJ, Parker MG: Nuclear factor RIP140 modulates transcriptional activation by the estrogen receptor. EMBO J 1995, 14:3741-3751.
26. On̄ate SA, Tsai SY, Tsai M-J, O'Malley BW: Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 1995, 270:1354-1357. The authors of this paper report the cloning of the gene encoding SRC-1, the first protein demonstrated to potentiate ligand-dependent transcriptional activity for several nuclear receptors. SRC-1 is the prototypic member of the SRC-1/TIF2 gene family, and in [27••] is shown to account for a significant fraction of p160.
27. Kamei Y, Xu L, Heinzel T, Torchia J, Kurokawa R, Gloss B, Lin S-C, Heyman R, Rose D, Glass C, Rosenfeld M: A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell 1996, 85:1-12. The authors of this paper demonstrate direct interactions between CBP/p300 and several nuclear receptors, in addition to direct interaction between CBP/p300 and SRC-1/N-CoA1 CBP/p300 are demonstrated to play essential coactivator roles for the RAR, on the basis of inhibition of RA-dependent transcription by microinjection of anti-CBP antibodies. Over-expression of CBP is demonstrated to relieve inhibition of AP-1 activity by retinotc acid, suggesting that AP-1 antagonism reflects competition for limiting amounts of CBP/p300 in cells. A full-length cDNA encoding SRC-1/N-CoA1 reveals that the amino terminus contains a PAS homology domain and represents a component of biochemically defined p160.
28. Yao T-P, Ku G, Zhou N, Scully R, Livingston DM: The nuclear hormone receptor coactivator SRC-1 is a specific target of p300. Proc Natl Acad Sci USA 1996, 93:10626-10631. This paper describes the cloning of the gene encoding SRC-1 on the basis of the protein's interaction with the carboxy-terminal domain of p300. This interaction is demonstrated to occur in cells within discrete regions of the nucleus. As in [27••], full-length SRC-1 is demonstrated to contain a PAS domain in its amino terminus.
29. Voegel JJ, Heine MJS, Zechel C, Chambon P, Gronemeyer H: TIF2, a 160 kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors. EMBO J 1996, 15:3667-3675. The authors report on the cloning of the gene, and functional characterization of the protein, encoding a second nuclear receptor coactivator that corresponds to biochemically defined p160. TIF2 is shown to be homologous to SRC-1/N-CoA1 and thus defines a new gene family. TIF2 potentiates ligand-dependent transcription by several nuclear receptors and is shown to contain an intrinsic activation domain.
30. Hong H, Kohli K, Trivedi A, Johnson DL, Stallcup MR: GRIP1, a novel mouse protein that serves as a transcriptional coactivator in yeast for the hormone binding domains of steroid receptors. Proc Natl Acad Sci USA 1996, 93:4948-4952.
31. Huang ZJ, Edery I, Rosbash M: PAS is a dimerization domain common to Drosophila period and several transcription factors. Nature 1993, 364:259-262.
32. Chakravarti D, LaMorte VJ, Nelson MC, Nakajima T, Schulman IG, Juguilon H, Montminy M, Evans RM: Role of CBP/p300 in nuclear receptor signalling. Nature 1996, 383:99-103. Together with [17•,27••], this paper demonstrates that CBP and p300 interact with nuclear receptors in a ligand-dependent manner and are required for ligand-dependent transcriptional responses.
33. Beato M, Herrlich P, Schütz G: Steroid hormone receptors: many actors in search of a plot. Cell 1995, 83:851-857.
34. Arias J, Alberts AS, Brindle P, Claret FX, Smeal T, Karin M, Feramisco J, Montminy M: Activation of cAMP and mitogen responsive genes relies on a common nuclear factor. Nature 1994, 370:226-229.
35. Eckner R, Yao T-P, Oldread E, Livingston DM: Interaction and functional collaboration of p300/CBP and bHLH proteins in muscle and B-cell differentiation. Genes Dev 1996, 10:2478-2490.
36. Smith CL, Oate SA, Tsai M-J, O'Malley BW: CREB binding protein acts synergistically with steroid receptor coactivator-1 to enhance steroid receptor-dependent transcription. Proc Natl Acad Sci USA 1996, 93:8884-8888.
37. Willy PJ, Umesono K, Ong ES, Evans RM, Heyman RA, Mangelsdorf DJ: LXR, a nuclear receptor that defines a distinct retinoic response pathway. Genes Dev 1995, 9:1033-1045.
38. Yang X-Y, Ogryzko W, Nishikawa J, Howard BH, Nakatani Y: A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A. Nature 1996, 382:319-324.
39. Lundblad JR, Kwok PS, Laurance ME, Harter ML, Goodman RH: Adenoviral E1A-associated protein p300 as a functional homologue of the transcriptional co-activator CBP. Nature 1995, 374:85-88.
40. Bannister AJ, Oehler T, Wilhelm D, Angel P, Kouzarides T: Stimulation of c-Jun activity by CBP: c-Jun residues Ser63/73 are required for CBP induced stimulation in vivo and CBP binding in vitro. Oncogene 1995, 11:2509-2514.
41. Bannister AJ, Kouzarides T: CBP-induced stimulation of c-Fos activity is abrogated by E1A. EMBO J 1995, 14:4758-4762.
42. Lee J-S, Galvin KM, See RH, Eckner R, Livingston D, Moran E, Shi Y: Relief of YY1 transcriptional repression by adenovirus E1A is mediated by E1A-associated protein p300. Genes Dev 1995, 9:1188-1198.
43. Dai P, Akimaru H, Tanaka Y, Hou D-X, Yasukawa T, Kanei-Ishii C, Takahashi T, Ishii S: CBP as a transcriptional coactivator of c-Myb. Genes Dev 1996, 10:528-540.
44. Bhattacharya S, Eckner R, Grossman S, Oldread E, Arany Z, D'Andrea A, Livingston DM: Cooperation of Stat2 and p300/CBP in signalling induced by interferon-α. Nature 1996, 383:344-347.
45. Petrij F, Giles RH, Dauwerse HG, Saris JJ, Hennekam RCM, Masuno M, Tommerup N, Van Ommen G-J, Goodman RH, Peters DJM, Breuning MH: Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP. Nature 1995, 376:348-351.
46. Borrow J, Stanton VPJ, Andresen JM, Becher R, Behm FG, Chaganti RSK, Civin CI, Disteche C, Dubé I, Frischauf AM et al.: The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. Nat Genet 1996, 14:33-41.
47. 70, for the androgen receptor in human prostate cells. Proc Natl Acad Sci USA 1996, 93:5517-5521.
48. Wurtz JM, Bourguet W, Renaud JP, Vivat V, Chambon P, Moras D, Gronemeyer H: A canonical structure for the ligand-binding domain of nuclear receptors. Nat Struct Biol 1996, 3:206
49. Horvai AE, Xu L, Korzus E, Brard G, Kalafus D, Mullen T-M, Rose DW, Rosenfeld MG, Glass CK: Nuclear integration of JAK/STAT and Ras/AP-1 signaling by CBP and p300. Proc Natl Acad Sci USA 1997, 94:1074-1079.
50. Zhang JJ, Vinkemeier U, Wei G, Chakravarti D, Horvath CM, Darnell JE Jr: Two contact regions between Stall and CBP/p300 in IFN-γ signaling. Proc Natl Acad Sci USA 1997, in press.